Amicus Historical Financial Ratios

FOLD Stock

USD 9.98 0.02 0.20%

Amicus Therapeutics is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 27.46 or Days Sales Outstanding of 76.09 will help investors to properly organize and evaluate Amicus Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

About Amicus Financial Ratios Analysis

Amicus TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Amicus Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Amicus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Amicus Therapeutics history.

Amicus Therapeutics Financial Ratios Chart

At present, Amicus Therapeutics' Book Value Per Share is projected to slightly grow based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 1.63, whereas Days Sales Outstanding is forecasted to decline to 76.09.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Amicus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Amicus Therapeutics sales, a figure that is much harder to manipulate than other Amicus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Amicus Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Book Value Per Share is projected to slightly grow based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 1.63, whereas Days Sales Outstanding is forecasted to decline to 76.09.

	2021	2022	2023	2024 (projected)
Payables Turnover	1.6	2.5	2.47	2.85
Days Of Inventory On Hand	284.01	225.21	583.75	486.23

Payables Turnover Days Of Inventory On Hand

Amicus Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.35	0.49	0.05	0.0	0.02	-0.29	-0.35	0.99	0.02	-0.1	-0.49	0.02	0.53	-0.18	0.51	-0.01	0.26	-0.36	0.34	0.25	0.48	0.04	0.12	0.27	0.27
Ptb Ratio	-0.35		-0.21	0.17	0.37	0.31	-0.41	1.0	-0.32	0.3	0.09	0.48	0.33	-0.61	-0.27	-0.46	-0.31	-0.86	0.37	0.03	-0.87	-0.32	-0.59	-0.49	-0.87	-0.92
Days Sales Outstanding	0.49	-0.21		0.04	-0.01	0.07	-0.25	-0.21	0.37	0.07	-0.29	-0.28	0.06	0.3	0.21	0.75	-0.07	0.21	-0.89	0.23	0.21	-0.12	0.03	-0.19	0.21	0.27
Book Value Per Share	0.05	0.17	0.04		0.97	0.98	-0.53	0.17	0.09	0.98	-0.77	0.23	0.98	-0.23	-0.54	0.06	-0.98	-0.15	0.04	0.63	-0.15	0.26	-0.22	-0.75	-0.14	-0.21
Free Cash Flow Yield	0.0	0.37	-0.01	0.97		0.99	-0.6	0.37	0.04	0.99	-0.7	0.33	0.99	-0.37	-0.57	-0.07	-0.99	-0.32	0.12	0.61	-0.33	0.15	-0.34	-0.8	-0.32	-0.4
Operating Cash Flow Per Share	0.02	0.31	0.07	0.98	0.99		-0.61	0.31	0.06	1.0	-0.77	0.25	1.0	-0.28	-0.49	-0.01	-1.0	-0.26	0.01	0.61	-0.27	0.15	-0.29	-0.83	-0.26	-0.32
Capex To Depreciation	-0.29	-0.41	-0.25	-0.53	-0.6	-0.61		-0.41	-0.3	-0.61	0.53	-0.12	-0.62	0.16	0.25	0.03	0.61	0.26	0.11	-0.74	0.28	0.0	0.02	0.68	0.27	0.37
Pb Ratio	-0.35	1.0	-0.21	0.17	0.37	0.31	-0.41		-0.32	0.3	0.09	0.48	0.33	-0.61	-0.27	-0.46	-0.31	-0.86	0.37	0.03	-0.87	-0.32	-0.59	-0.49	-0.87	-0.92
Ev To Sales	0.99	-0.32	0.37	0.09	0.04	0.06	-0.3	-0.32		0.06	-0.1	-0.46	0.06	0.5	-0.24	0.42	-0.05	0.23	-0.25	0.36	0.23	0.52	0.03	0.12	0.24	0.23
Free Cash Flow Per Share	0.02	0.3	0.07	0.98	0.99	1.0	-0.61	0.3	0.06		-0.78	0.26	1.0	-0.28	-0.49	-0.01	-1.0	-0.26	0.01	0.62	-0.26	0.15	-0.28	-0.83	-0.25	-0.32
Roic	-0.1	0.09	-0.29	-0.77	-0.7	-0.77	0.53	0.09	-0.1	-0.78		0.03	-0.77	-0.07	-0.02	-0.13	0.78	-0.18	0.36	-0.6	-0.17	0.01	-0.23	0.78	-0.18	-0.15
Inventory Turnover	-0.49	0.48	-0.28	0.23	0.33	0.25	-0.12	0.48	-0.46	0.26	0.03		0.24	-0.96	-0.44	-0.55	-0.26	-0.22	0.47	0.3	-0.24	-0.42	-0.11	-0.37	-0.24	-0.38
Net Income Per Share	0.02	0.33	0.06	0.98	0.99	1.0	-0.62	0.33	0.06	1.0	-0.77	0.24		-0.28	-0.48	-0.01	-1.0	-0.28	0.01	0.6	-0.29	0.14	-0.3	-0.83	-0.28	-0.34
Days Of Inventory On Hand	0.53	-0.61	0.3	-0.23	-0.37	-0.28	0.16	-0.61	0.5	-0.28	-0.07	-0.96	-0.28		0.46	0.6	0.29	0.44	-0.51	-0.21	0.45	0.46	0.28	0.37	0.46	0.56
Payables Turnover	-0.18	-0.27	0.21	-0.54	-0.57	-0.49	0.25	-0.27	-0.24	-0.49	-0.02	-0.44	-0.48	0.46		0.02	0.48	0.29	-0.56	-0.51	0.3	-0.5	0.38	0.19	0.29	0.39
Capex To Revenue	0.51	-0.46	0.75	0.06	-0.07	-0.01	0.03	-0.46	0.42	-0.01	-0.13	-0.55	-0.01	0.6	0.02		0.01	0.37	-0.67	0.14	0.38	0.46	0.07	0.1	0.38	0.44
Cash Per Share	-0.01	-0.31	-0.07	-0.98	-0.99	-1.0	0.61	-0.31	-0.05	-1.0	0.78	-0.26	-1.0	0.29	0.48	0.01		0.26	-0.01	-0.62	0.27	-0.13	0.28	0.84	0.26	0.32
Pocfratio	0.26	-0.86	0.21	-0.15	-0.32	-0.26	0.26	-0.86	0.23	-0.26	-0.18	-0.22	-0.28	0.44	0.29	0.37	0.26		-0.36	0.2	1.0	0.21	0.78	0.24	1.0	0.95
Interest Coverage	-0.36	0.37	-0.89	0.04	0.12	0.01	0.11	0.37	-0.25	0.01	0.36	0.47	0.01	-0.51	-0.56	-0.67	-0.01	-0.36		-0.01	-0.37	0.21	-0.16	0.12	-0.37	-0.44
Capex To Operating Cash Flow	0.34	0.03	0.23	0.63	0.61	0.61	-0.74	0.03	0.36	0.62	-0.6	0.3	0.6	-0.21	-0.51	0.14	-0.62	0.2	-0.01		0.18	0.24	0.32	-0.61	0.2	0.03
Pfcf Ratio	0.25	-0.87	0.21	-0.15	-0.33	-0.27	0.28	-0.87	0.23	-0.26	-0.17	-0.24	-0.29	0.45	0.3	0.38	0.27	1.0	-0.37	0.18		0.2	0.77	0.25	1.0	0.97
Days Payables Outstanding	0.48	-0.32	-0.12	0.26	0.15	0.15	0.0	-0.32	0.52	0.15	0.01	-0.42	0.14	0.46	-0.5	0.46	-0.13	0.21	0.21	0.24	0.2		-0.01	0.2	0.21	0.21
Income Quality	0.04	-0.59	0.03	-0.22	-0.34	-0.29	0.02	-0.59	0.03	-0.28	-0.23	-0.11	-0.3	0.28	0.38	0.07	0.28	0.78	-0.16	0.32	0.77	-0.01		0.11	0.77	0.67
Roe	0.12	-0.49	-0.19	-0.75	-0.8	-0.83	0.68	-0.49	0.12	-0.83	0.78	-0.37	-0.83	0.37	0.19	0.1	0.84	0.24	0.12	-0.61	0.25	0.2	0.11		0.24	0.3
Ev To Operating Cash Flow	0.27	-0.87	0.21	-0.14	-0.32	-0.26	0.27	-0.87	0.24	-0.25	-0.18	-0.24	-0.28	0.46	0.29	0.38	0.26	1.0	-0.37	0.2	1.0	0.21	0.77	0.24		0.96
Pe Ratio	0.27	-0.92	0.27	-0.21	-0.4	-0.32	0.37	-0.92	0.23	-0.32	-0.15	-0.38	-0.34	0.56	0.39	0.44	0.32	0.95	-0.44	0.03	0.97	0.21	0.67	0.3	0.96

Click cells to compare fundamentals

Amicus Therapeutics Account Relationship Matchups

Amicus Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	12.85	22.91	10.26	10.72	10.49	9.96
Ptb Ratio	4.92	20.87	10.2	28.68	26.15	27.46
Days Sales Outstanding	66.66	65.65	62.93	73.39	80.09	76.09
Book Value Per Share	1.98	1.11	1.13	0.43	0.54	0.57
Free Cash Flow Yield	(0.12)	(0.0396)	(0.0658)	(0.0483)	(0.0183)	(0.0192)
Operating Cash Flow Per Share	(1.04)	(0.9)	(0.75)	(0.58)	(0.23)	(0.25)
Stock Based Compensation To Revenue	0.32	0.24	0.19	0.23	0.22	0.2
Capex To Depreciation	4.19	0.36	0.63	0.7	0.95	1.63
Pb Ratio	4.92	20.87	10.2	28.68	26.15	27.46
Ev To Sales	13.22	23.98	10.9	11.64	10.98	10.43
Roic	(0.54)	(0.49)	(0.48)	(0.28)	(0.13)	(0.14)
Inventory Turnover	1.56	1.59	1.29	1.62	0.63	1.0
Days Of Inventory On Hand	233.35	229.93	284.01	225.21	583.75	486.23
Payables Turnover	1.01	1.82	1.6	2.5	2.47	2.85
Research And Ddevelopement To Revenue	1.57	1.18	0.89	0.84	0.38	0.36
Capex To Revenue	0.11	0.0124	0.0127	0.0114	0.0186	0.0177
Cash Per Share	1.88	1.87	1.78	1.02	0.97	0.92
Pocfratio	(9.35)	(25.62)	(15.48)	(21.19)	(60.62)	(57.59)
Interest Coverage	(15.94)	(10.87)	(6.16)	(5.51)	(1.47)	(1.54)
Capex To Operating Cash Flow	(0.0799)	(0.0138)	(0.0192)	(0.0226)	(0.11)	(0.1)
Pfcf Ratio	(8.66)	(25.27)	(15.19)	(20.72)	(54.73)	(51.99)
Days Payables Outstanding	360.99	200.62	227.83	145.75	147.85	140.46
Income Quality	0.86	0.7	0.84	0.81	0.46	0.43
Roe	(0.75)	(0.97)	(0.81)	(1.92)	(0.95)	(0.99)
Ev To Operating Cash Flow	(9.62)	(26.82)	(16.44)	(23.01)	(63.49)	(60.31)
Pe Ratio	(6.57)	(21.59)	(12.52)	(14.92)	(27.63)	(26.25)
Ev To Free Cash Flow	(8.91)	(26.45)	(16.13)	(22.5)	(57.32)	(54.45)
Earnings Yield	(0.15)	(0.0463)	(0.0799)	(0.067)	(0.0362)	(0.038)
Intangibles To Total Assets	0.28	0.26	0.25	0.24	0.3	0.39
Net Debt To E B I T D A	(0.2)	(1.15)	(0.96)	(1.52)	(2.15)	(2.04)
Current Ratio	4.04	4.47	4.09	3.05	2.88	2.74
Tangible Book Value Per Share	1.06	0.25	0.32	(0.34)	(0.2)	(0.21)
Receivables Turnover	5.48	5.56	5.8	4.97	4.56	3.53
Graham Number	8.13	5.16	4.85	2.8	2.5	2.38
Shareholders Equity Per Share	1.98	1.11	1.13	0.43	0.54	0.57
Debt To Equity	0.33	1.54	1.43	3.67	2.47	2.6

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.34)

Revenue Per Share

1.629

Quarterly Revenue Growth

0.367

Return On Assets

0.0116

Return On Equity

(0.67)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Amicus Historical Financial Ratios

About Amicus Financial Ratios Analysis

Amicus Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

Amicus Therapeutics fundamentals Correlations

Amicus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amicus Therapeutics fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Cash Per Share	- 1.0	Net Income Per Share
Cash Per Share	- 1.0	Free Cash Flow Per Share
Cash Per Share	- 1.0	Operating Cash Flow Per Share
Cash Per Share	- 0.99	Free Cash Flow Yield
Cash Per Share	- 0.98	Book Value Per Share
Days Of Inventory On Hand	- 0.96	Inventory Turnover